Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies

Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies#Press #Release #Itepekimab #met #primary #endpoint #COPD #phase #studies